Latest news with #Sanofi
Zawya
7 hours ago
- Business
- Zawya
NMSS and Erth Zayed Philanthropies sign AED 25mln grant agreement to mark World MS Day
Strategic collaboration to drive the UAE's national MS agenda. Abu Dhabi – The National Multiple Sclerosis Society (NMSS) has signed a strategic agreement with Erth Zayed Philanthropies to advance its national multiple sclerosis (MS) agenda. As part of this agreement, Erth Zayed Philanthropies will contribute AED 25 million to support NMSS in delivering its core priorities, including advancing UAE's first National Coalition for MS, a multi-sector platform to improve care, research, and inclusion across the country. The agreement was signed by Her Excellency Dr. Fatima Al Kaabi, Vice Chair of the National Multiple Sclerosis Society, and a representative from Erth Zayed Philanthropies during a formal ceremony in Abu Dhabi. The announcement of this strategic agreement coincides with World MS Day, marked this year under the global theme 'My MS Diagnosis: Navigating MS Together,' which highlights the importance of early detection and community support. This year, Erth Zayed Philanthropies joins the National Coalition for MS as a founding partner, marking a pivotal step in the UAE's efforts to advance equitable MS care and inclusion. This strategic partnership reinforces the UAE's commitment to enhancing MS care, accelerating research, and advancing equity, catalyzing broader multi-sector engagement to shape a more inclusive and transformative national response. Coalition members include Sanofi, Axios International, PureHealth and Manzil Healthcare Services, each playing a vital role in advancing care, awareness, and system-wide impact. Her Excellency Dr. Fatima Al Kaabi, Vice Chair of the National Multiple Sclerosis Society, said: 'The establishment of the National Coalition for MS is a defining step in our mission to drive equitable access to MS care. This work is inspired by the legacy of our late Founding Father, Sheikh Zayed bin Sultan Al Nahyan, whose vision was rooted in dignity, inclusion, and access to quality care for all. It is sustained by the leadership of His Highness Sheikh Mohamed bin Zayed Al Nahyan, whose commitment continues to shape the future of health and reinforce the UAE's position as a global leader in innovative, people-centered healthcare. 'On World MS Day, we are proud to join the international community, not only in raising awareness, but in taking meaningful, coordinated action that has the potential to transform outcomes for people living with MS. Today, we are laying the foundations for long-term impact rooted in compassion, powered by collaboration, and guided by a shared responsibility to ensure that every member of our community has the opportunity to live a full and dignified life.' The grant from Erth Zayed Philanthropies will directly support NMSS in delivering on its key priorities and enabling the National Coalition for MS to address the most pressing challenges faced by people living with MS in the UAE. First announced on World MS Day in 2024, the National Coalition for MS was convened by NMSS to bring together government entities, healthcare providers, insurance and pharmaceutical companies, and educational institutions under a unified national agenda for MS. The Coalition's priorities for 2025-2026 are focused on improving access to patient support resources, promoting inclusive workplace policies, strengthening the skills of healthcare professionals through specialized training, increasing public understanding of MS to enable earlier diagnosis, and ensuring long-term sustainability through coordinated fundraising and investment in research. Together, these priorities form an action-oriented framework designed to mobilize resources, strengthen inclusion across sectors, and ensure that the UAE is a world leader in MS care. As the Coalition moves into its implementation phase, its priorities will continue to be shaped by the voices and experiences of the MS community, ensuring that their needs, priorities, and aspirations drive every step of the journey. Anchored in shared responsibility and measurable impact, the Coalition's members are onboarded to lead or contribute to key initiatives, with defined commitments that span one to two years depending on the scope of work. The Coalition's priorities reflect a commitment to evidence-based solutions. Since its establishment, NMSS has invested AED 6.5 million in MS research, with the next NMSS research grant cycle set to launch on 23 June 2025. As the Coalition transitions into its implementation phase, NMSS continues to call on stakeholders across sectors, from policymakers and healthcare institutions to academic bodies and donors, to join this pivotal movement. About the National Multiple Sclerosis Society Established in 2022 under the Ministry of Community Empowerment, the National Multiple Sclerosis Society (NMSS) is a UAE-based NGO created to better the lives of people living with multiple sclerosis (MS) and their communities in the UAE through education, advocacy and advancing global efforts to finding a cure for MS. NMSS is governed by a board of trustees, advised by a local and international Strategic Advisory Committee and Medical Advisory Committee, and supported by MS ambassadors and volunteers. Together, they ensure that people living with MS have access to high-quality care and get the guidance they need through reliable resources. NMSS works with leading national medical institutions and renowned global partners to build a trusted network of healthcare providers and support organizations. The society aims to raise awareness of MS, create a holistic ecosystem for the MS community in the UAE, and provide support and resources for individuals affected by MS. For more information about MS and the NMSS, please visit Visit the NMSS's official social media platforms for the most recent updates and insights. Instagram: NMSsocietyUAE Facebook: National MS Society UAE LinkedIn: National Multiple Sclerosis Society UAE YouTube: NMSSocietyUAE X: NMSsocietyUAE For media inquiries, please contact: Miral Zalabani Account Director NMSS@ About Erth Zayed Philanthropies Erth Zayed Philanthropies is a network foundation established in November 2024 to coordinate and strengthen the UAE's philanthropic efforts worldwide. Operating from Abu Dhabi under the patronage of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the United Arab Emirates, the Foundation is chaired by His Highness Sheikh Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes' Affairs and Chairman of the International Humanitarian and Philanthropic Council. Erth Zayed Philanthropies promotes philanthropy as a catalyst, complementing other forms of aid. Its affiliates deliver initiatives across the UAE and in more than 90 countries, focusing on community service, healthcare, education, environmental stewardship, agriculture and food security, and economic empowerment. Through direct programmes, strategic partnerships, and catalytic funds, the Foundation supports long-term, values-led solutions to humanitarian and development challenges.
Yahoo
19 hours ago
- Business
- Yahoo
Sanofi (ENXTPA:SAN) Reports Positive Phase 3 Results for Itepekimab in COPD Trial
Sanofi announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the company's share price fell 5% over the last week, contrasting with a 2% rise in the broader market. This decline may reflect investors' reactions to other company initiatives, such as its partnership with Stagecoach Performing Arts to raise awareness of autoimmune Type 1 diabetes. These positive developments, although promising, were not enough to counterbalance the broader market's upward trend, contributing weight against Sanofi's price movement. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Uncover the next big thing with financially sound penny stocks that balance risk and reward. The recent successful completion of Sanofi's AERIFY-1 trial could have a positive impact on its revenue and earnings forecasts by strengthening its position in the COPD treatment market. However, despite these promising developments, the company's share price experienced a 5% decline in the past week, contrasting with the broader market's 2% rise. This movement might reflect investor reactions to other company initiatives, such as the partnership with Stagecoach Performing Arts, and broader market trends. Looking at a longer-term context, Sanofi's shares have delivered a total return of 19.59% over the past five years. Recent performance has exceeded the French Pharmaceuticals industry and market, which returned 4% and 4.5% declines respectively over the last year. Such outperformance indicates resilience amidst industry challenges and market volatility. Please consider the current share price of €95.9 against the consensus price target of €117.17, indicating a potential upside potential of approximately 18.5%. This price target is based on expectations of revenue reaching €51.2 billion and earnings of €10.2 billion by 2028, trading on a PE ratio of 16.1x. Analysts are assuming that Sanofi will enhance its growth trajectory driven by its innovative treatments and efficient operational strategies. Assess Sanofi's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Insider
19 hours ago
- Business
- Business Insider
Barclays Remains a Buy on Sanofi (SNYNF)
Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) yesterday and set a price target of €125.00. The company's shares closed yesterday at $99.97. Confident Investing Starts Here: Field covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, AstraZeneca, and Roche Holding AG. According to TipRanks, Field has an average return of -1.5% and a 39.02% success rate on recommended stocks. In addition to Barclays, Sanofi also received a Buy from Bank of America Securities's Sachin Jain in a report issued yesterday. However, on the same day, J.P. Morgan maintained a Hold rating on Sanofi (Other OTC: SNYNF).
Yahoo
2 days ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a key report revealed softening inflation. Regeneron Pharmaceuticals shares plummeted after the company's experimental COPD treatment fell short of expectations in a late-stage clinical trial. Makeup seller Ulta Beauty reported better-than-expected quarterly sales and profits, and its shares U.S. equities indexes were mixed in the final session of the holiday-shortened trading week as President Donald Trump reverted to an antagonistic tone on trade with China and the latest Personal Consumption Expenditures data showed that inflation fell more than expected in April. The S&P 500 staged a Friday-afternoon rally, coming back from deeper in negative territory to end with a loss of less than 0.1%. The Nasdaq was down 0.3%, while the Dow held onto a gain of 0.1%. The Nasdaq and S&P logged their strongest months since 2023. Read Investopedia's full coverage of today's trading here. Shares of Regeneron Pharmaceuticals (REGN) plunged 19%, dropping the most of any stock in the S&P 500. The losses came after an experimental treatment for chronic obstructive pulmonary disease in former smokers, developed by Regeneron in collaboration with Sanofi (SNY), failed to meet primary endpoints in a Phase 3 trial. The companies said they are reviewing the data and will work with regulators to outline potential next steps. U.S.-listed shares of Sanofi slid 5.7%. Cooper Cos. (COO) shares dropped 15% after the contact lens manufacturer reduced its full-year outlook for organic growth while edging out consensus sales and adjusted profit estimates with its fiscal second-quarter results. Analysts at JPMorgan downgraded Cooper stock to "neutral" from "overweight," citing the company's uneven execution and the possibility of a sustained slowdown in market trends. Shares of Eastman Chemical (EMN), known for its specialty plastics and adhesives, fell 3.8%. The company announced that its molecular recycling project in Longview, Texas, which was previously expected to receive $375 million in public funding, was among 24 awards revoked by the Department of Energy. Cosmetics retailer Ulta Beauty (ULTA) topped sales and profit estimates for its fiscal first quarter and lifted its outlook for the full year. CEO Kecia Steelman highlighted contributions from new and exclusive brands as well as strong sales of fragrance products, noting that consumers were turning to beauty products "as a comfort and escape from the stress of macro uncertainty." Ulta shares skyrocketed 12%, scoring the S&P 500's top daily performance. Shares of Palantir Technologies (PLTR) jumped 7.7% as a New York Times report indicated that the Trump administration has expanded the data analytics software firm's role in government data-sharing initiatives. The tech company, which has lucrative contracts with the federal government and Defense Department, is reportedly engaged in efforts to improve access to data across government agencies. Enphase Energy (ENPH) stock advanced 5.5%. Shares of the solar microinverter manufacturer came under heavy pressure alongside other renewable energy players after the House of Representatives passed a tax and spending bill that would eliminate certain incentives for clean energy projects, including a federal tax credit for the installation of solar rooftop systems. Enphase Energy shares dropped to a 52-week low on May 22, the day the bill was passed, but have staged a partial recovery since. Costco Wholesale (COST) stock added 3.1% after the bulk retailer's quarterly revenue and net income edged out consensus forecasts. Same-store sales also grew more than expected. Analysts have suggested that high-margin membership revenue could provide Costco with some flexibility to navigate tariff-related cost pressure without raising prices. Read the original article on Investopedia
Yahoo
2 days ago
- Business
- Yahoo
Regeneron stock sinks over trial data for smoker's lungs drug
Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co-developed with Sanofi (SNY, Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to speak more on this. Regeneron has put up a bid to acquire genetic testing firm 23andMe (ME) after the company filed for bankruptcy. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Well shares of Regeneron Pharmaceuticals, they're sinking. The move lower comes as trial results for the company's co-developed experimental drug with Sanofi disappoints. Joining us now with more is Yahoo Finance's, Angelique Clamontange. That's right, Josh. They got news of uh, the drug not necessarily meeting the end points that it was supposed to. The stock down about 19%, uh closing at that rate today. And we saw that this is a drug that the company had uh, had co-developed with Sanofi and it's supposed to address chronic obstructive pulmonary disease and they're looking at former smokers who have basically inflammation or damage to their lung tissue, making it harder to breathe. Now the primary endpoint of reducing that kind of obstruction they had one trial that met the endpoint and one that didn't. So that mixed result is really what caused the pressure on the stock today. And this of course coming after Regeneron came to if you will save the day and took 23andMe out of bankruptcy recently. So they'd really gotten a bump in their stock because of that and now just kind of washed away and hitting a four-year low today. And Ange, why does this matter more for Regeneron than Sanofi? Yeah, Regeneron has had a little bit of questions surrounding it. Um, you know, some of the uh, analysts did uh, have looked at its pipeline and that's been sort of where the pressure's coming from. We saw some downgrades today just on this news. RBC and Wells Fargo punishing that stock because of the, the news today. Regeneron doesn't have any near term blockbusters and this was supposed to essentially be it. It's important to note that they already are working with Sanofi on a different product that did hit, that has been on the market. Dupixent, and it did get approved for COPD last year. That drug brings in about 14 billion and so this was looking to be sort of on the same range. Uh, even though that drug does address a number of other diseases but it could have been another blockbuster for Regeneron and now without that their near term pipeline is in question. Ange, thanks so much, appreciate it. Have a great weekend. You too.
